{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:14:29Z","timestamp":1789564469022,"version":"build-2803163510"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Depression is a common comorbidity of adult attention-deficit\/hyperactivity disorder (ADHD), and the combination of methylphenidate and selective serotonin reuptake inhibitors (SSRIs) is a frequently prescribed treatment. However, there is limited clinical evidence on the safety of this medication combination in adults with ADHD.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the safety of administering a combination of SSRI and methylphenidate in adults with ADHD and comorbid depression.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study obtained data from a nationwide claims database in South Korea from January 2016 to February 2021. Participants were adults aged 18 years or older with a diagnosis of ADHD and depressive disorder who were prescribed methylphenidate. Comparisons of 4 groups who received prescriptions were conducted: (1) SSRI plus methylphenidate (hereafter, SSRI) group vs methylphenidate-only group and (2) methylphenidate plus fluoxetine (hereafter, fluoxetine) group vs methylphenidate plus escitalopram (hereafter, escitalopram) group (compared to find a preferable treatment option). Data analysis was conducted between July and December 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>New users of the methylphenidate and SSRI combination among adults with both ADHD and depressive disorder.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>A total of 17 primary and secondary outcomes, including neuropsychiatric and other events, were assessed, with respiratory tract infection used as a control outcome. Groups were matched at a 1:1 ratio using a propensity score to balance confounders. A Cox proportional hazards regression model was used to calculate hazard ratio (HRs) and 95% CIs. Subgroup analysis by sex and sensitivity analyses in varying epidemiologic settings were conducted.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 17 234 adults with ADHD (mean [SD] age at study entry, 29.4 [10.8] years; 9079 females [52.7%]). There was no difference in the risk of outcomes between the methylphenidate-only and SSRI groups, except for a lower risk of headache in the SSRI group (HR, 0.50; 95% CI, 0.24-0.99). In sensitivity analyses of fluoxetine vs escitalopram, the risk of hypertension (HR: 1:n matching, 0.26; 95% CI, 0.08-0.67) and hyperlipidemia (HR: 1:n matching, 0.23; 95% CI, 0.04-0.81) was lower in the fluoxetine group than in the escitalopram group.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of this study revealed no significant increase in adverse event risk associated with use of SSRI plus methylphenidate vs methylphenidate alone in adults with ADHD and comorbid depression. Instead, the combination was associated with a lower risk of headache.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.38398","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:21:19Z","timestamp":1728487279000},"page":"e2438398","source":"Crossref","is-referenced-by-count":9,"title":["Combined Methylphenidate and Selective Serotonin Reuptake Inhibitors in Adults With Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1001","volume":"7","author":[{"given":"Dong Yun","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea"},{"name":"Department of Medical Sciences, Graduate School of Ajou University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmi","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Ajou University School of Medicine, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea"},{"name":"Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"issue":"3","key":"zoi241114r1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","article-title":"Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.","volume":"194","author":"Simon","year":"2009","journal-title":"Br J Psychiatry"},{"issue":"10222","key":"zoi241114r2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder.","volume":"395","author":"Posner","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"zoi241114r3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1017\/S0033291708004236","article-title":"Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition.","volume":"39","author":"B\u00e1lint","year":"2009","journal-title":"Psychol Med"},{"issue":"1","key":"zoi241114r4","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/nrdp.2015.20","article-title":"Attention-deficit\/hyperactivity disorder.","volume":"1","author":"Faraone","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"zoi241114r5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12888-017-1463-3","article-title":"Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.","volume":"17","author":"Katzman","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"10","key":"zoi241114r6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"zoi241114r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43597","article-title":"Risk of cardiovascular diseases associated with medications used in attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis.","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi241114r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.6815","article-title":"Association between pharmacological treatment of attention-deficit\/hyperactivity disorder and long-term unemployment among working-age individuals in Sweden.","volume":"5","author":"Li","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi241114r9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","article-title":"The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.","volume":"163","author":"Kessler","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi241114r10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/08039480500520665","article-title":"ADHD in adults: a study of clinical characteristics, impairment and comorbidity.","volume":"60","author":"Torgersen","year":"2006","journal-title":"Nord J Psychiatry"},{"issue":"3","key":"zoi241114r11","doi-asserted-by":"publisher","first-page":"26675","DOI":"10.4088\/PCC.09m00861gry","article-title":"Attention-deficit\/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the International Mood Disorders Collaborative Project.","volume":"12","author":"McIntyre","year":"2010","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"10","key":"zoi241114r12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1176\/appi.ajp.2016.15091207","article-title":"Treatment controversies in adult ADHD.","volume":"173","author":"McGough","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"10","key":"zoi241114r13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2165\/00003088-200140100-00004","article-title":"Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.","volume":"40","author":"Markowitz","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"zoi241114r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/cap.1993.3.1","article-title":"Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder.","volume":"3","author":"Gammon","year":"1993","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi241114r15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.9758\/cpn.2022.20.1.143","article-title":"Comparison between atomoxetine and OROS methylphenidate as an adjunctive to SSRIs in attention-deficit\/hyperactivity disorder adults with comorbid partially responsive major depressive disorder: a head-to-head, 12-week, randomized, rater-blinded clinical trial.","volume":"20","author":"Shim","year":"2022","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"zoi241114r16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuropharm.2014.08.024","article-title":"Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor.","volume":"89","author":"Van Waes","year":"2015","journal-title":"Neuropharmacology"},{"key":"zoi241114r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2023.100127","article-title":"Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration.","volume":"8","author":"Senior","year":"2023","journal-title":"Addict Neurosci"},{"key":"zoi241114r18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jad.2021.06.020","article-title":"Adult ADHD, executive function, depressive\/anxiety symptoms, and quality of life: a serial two-mediator model.","volume":"293","author":"Zhang","year":"2021","journal-title":"J Affect Disord"},{"issue":"10","key":"zoi241114r19","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1017\/S0033291723000120","article-title":"Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit\/hyperactivity disorder with comorbid depression: the ASSURE study.","volume":"53","author":"Kim","year":"2023","journal-title":"Psychol Med"},{"key":"zoi241114r20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/CER.S40357","article-title":"A tool for assessing the feasibility of comparative effectiveness research.","volume":"3","author":"Walker","year":"2013","journal-title":"Comp Eff Res"},{"key":"zoi241114r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103857","article-title":"Safety outcomes of antipsychotics classes in drug-na\u00efve patients with first-episode schizophrenia: a nationwide cohort study in South Korea.","volume":"91","author":"Lee","year":"2024","journal-title":"Asian J Psychiatr"},{"key":"zoi241114r22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3233\/SHTI231108","article-title":"Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research.","volume":"310","author":"Schuemie","year":"2024","journal-title":"Stud Health Technol Inform"},{"key":"zoi241114r23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jpeds.2018.12.033","article-title":"A comparison of pediatric and adult safety studies for antipsychotic and antidepressant drugs submitted to the United States Food and Drug Administration.","volume":"208","author":"Liu","year":"2019","journal-title":"J Pediatr"},{"issue":"6","key":"zoi241114r24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/01.jcp.0000246212.03530.fd","article-title":"A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.","volume":"26","author":"Patkar","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"zoi241114r25","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1111\/jth.12757","article-title":"Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia: a hospital-based cohort study.","volume":"12","author":"Lindqvist","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"8","key":"zoi241114r26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jaac.2019.06.010","article-title":"Attention-deficit\/hyperactivity disorder medication and unintentional injuries in children and adolescents.","volume":"59","author":"Ghirardi","year":"2020","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"zoi241114r27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00787-016-0929-z","article-title":"Impact of depressive\/anxiety symptoms on the quality of life of adolescents with ADHD: a community-based 1-year prospective follow-up study.","volume":"26","author":"Pan","year":"2017","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"zoi241114r28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.yebeh.2013.12.028","article-title":"Headache and attention deficit and hyperactivity disorder in children: common condition with complex relation and disabling consequences.","volume":"32","author":"Parisi","year":"2014","journal-title":"Epilepsy Behav"},{"issue":"1","key":"zoi241114r29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-016-0675-0","article-title":"Migraine in childhood: biobehavioural or psychosomatic disorder?","volume":"17","author":"Guidetti","year":"2016","journal-title":"J Headache Pain"},{"issue":"3","key":"zoi241114r30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1744-6163.2009.00221.x","article-title":"Antidepressants and sleep: a review.","volume":"45","author":"Holshoe","year":"2009","journal-title":"Perspect Psychiatr Care"},{"issue":"3","key":"zoi241114r31","first-page":"170","article-title":"Effects of antidepressant drugs on emotion.","volume":"29","author":"Serra","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"zoi241114r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache.","volume":"10","author":"Jackson","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"zoi241114r33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4088\/JCP.v58n0106b","article-title":"Paroxetine prevents migraines.","volume":"58","author":"Hays","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"zoi241114r34","first-page":"330","article-title":"Paroxetine as migraine prophylaxis.","volume":"56","author":"Black","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi241114r35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/0333102416640501","article-title":"Serotonergic mechanisms in the migraine brain: a systematic review.","volume":"37","author":"Deen","year":"2017","journal-title":"Cephalalgia"},{"issue":"3","key":"zoi241114r36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.9758\/cpn.2016.14.3.250","article-title":"Association of polymorphisms within the serotonin receptor genes 5-HTR1A, 5-HTR1B, 5-HTR2A and 5-HTR2C and migraine susceptibility in a Turkish population.","volume":"14","author":"Y\u00fccel","year":"2016","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"zoi241114r37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jad.2018.04.047","article-title":"Meta-analysis: second generation antidepressants and headache.","volume":"236","author":"Telang","year":"2018","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi241114r38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s13311-013-0230-5","article-title":"The treatment of tremor.","volume":"11","author":"Schneider","year":"2014","journal-title":"Neurotherapeutics"},{"key":"zoi241114r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120194","article-title":"Medications used to treat tremors.","volume":"435","author":"Frei","year":"2022","journal-title":"J Neurol Sci"},{"issue":"2","key":"zoi241114r40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1017\/cjn.2015.365","article-title":"Gender and age determinants of psychogenic movement disorders: a clinical profile of 73 patients.","volume":"43","author":"Kamble","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"zoi241114r41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12883-018-1149-6","article-title":"Comorbidity of migraine with ADHD in adults.","volume":"18","author":"Hansen","year":"2018","journal-title":"BMC Neurol"},{"issue":"1","key":"zoi241114r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpsy.2023.100228","article-title":"The association between pain and psychiatric conditions in adolescents: the impact of gender and ADHD diagnosis.","volume":"38","author":"Lundqvist","year":"2024","journal-title":"Eur J Psychiatry"},{"issue":"3","key":"zoi241114r43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/cap.1996.6.165","article-title":"Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series.","volume":"6","author":"Findling","year":"1996","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi241114r44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12265-019-09888-z","article-title":"Gender differences in hypertension.","volume":"13","author":"Song","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"issue":"12","key":"zoi241114r45","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.4088\/JCP.v67n1219","article-title":"Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study.","volume":"67","author":"Raeder","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi241114r46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4306\/pi.2013.10.2.148","article-title":"Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study.","volume":"10","author":"Beyazy\u00fcz","year":"2013","journal-title":"Psychiatry Investig"},{"issue":"8","key":"zoi241114r47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/da.20379","article-title":"Depression and the metabolic syndrome: gender-dependent associations.","volume":"25","author":"Toker","year":"2008","journal-title":"Depress Anxiety"},{"issue":"1","key":"zoi241114r48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clinthera.2020.12.003","article-title":"A narrative review of sex differences in eating disorders: is there a biological basis?","volume":"43","author":"Culbert","year":"2021","journal-title":"Clin Ther"},{"issue":"9","key":"zoi241114r49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239257","article-title":"The female side of pharmacotherapy for ADHD-a systematic literature review.","volume":"15","author":"Kok","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"zoi241114r50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021551","article-title":"Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.","volume":"6","author":"Ye","year":"2011","journal-title":"PLoS One"},{"issue":"1-3","key":"zoi241114r51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2004.01.036","article-title":"Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems.","volume":"488","author":"Giorgetti","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"zoi241114r52","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.704281","article-title":"Antidepressant drugs effects on blood pressure.","volume":"8","author":"Calvi","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"zoi241114r53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003053","article-title":"Dyslipidemia and the risk of developing hypertension in a working-age male population.","volume":"5","author":"Otsuka","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824665\/lee_2024_oi_241114_1727811694.05188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:21:22Z","timestamp":1728487282000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38398","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}